CD4+CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia

International Journal of Cancer

Volumn 121, Issue 8, 2007, Pages 1749-1755

  Molling, Johan W ^a   De Gruijl, Tanja D ^a   Glim, Judith ^a   Moreno, Maria ^a   Rozendaal, Lawrence ^a   Meijer, Chris J L M ^a   Van Den Eertwegh, Alfons J M ^a   Scheper, Rik J ^a   Von Blomberg, Mary E ^a   Bontkes, Hetty J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CIN; HPV type 16; Invariant NKT cells; Persistence; Regulatory T cells

Indexed keywords

CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; PROTEIN E7; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER T CELL; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROGNOSIS; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CARCINOGENESIS; AGED; CARCINOMA; DISEASE COURSE; HELPER CELL; IMMUNOLOGY; MIDDLE AGED; NATURAL KILLER CELL; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ADULT; AGED; ANTIGENS, CD4; CARCINOMA; DISEASE PROGRESSION; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; UTERINE CERVICAL NEOPLASMS;

EID: 34548666183     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22894     Document Type: Article

References (49)

1. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-52.
2. Mills KH, McGuirk P. Antigen-specific regulatory T cells - their induction and role in infection. Semin Immunol 2004;16:107-17.
3. Vigouroux S, Yvon E, Biagi E, Brenner MK. Antigen-induced regulatory T cells. Blood 2004;104:26-33.
4. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606-12.
5. +CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005;106:2018-25.
6. + T cells. J Immunol 2005;175:1483-90.
7. Dejaco C, Duftner C, Schirmer M. Are regulatory T-cells linked with aging? Exp Gerontol 2006;41:339-45.
8. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000;21:573-83.
9. Spada FM, Koezuka Y, Porcelli SA. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 1998;188:1529-34.
10. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V(α)24 natural killer T cells. J Exp Med 2002; 195:637-41.
11. Fuji N, Ueda Y, Fujiwara H, Toh T, Yoshimura T, Yamagishi H. Antitumor effect of α-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver. Clin Cancer Res 2000;6:3380-7.
12. Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, Saiki I. IFN-γ-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, α-galactosylceramide. Blood 2002;100:1728-33.
13. Chen YG, Choisy-Rossi CM, Holl TM, Chapman HD, Besra GS, Porcelli SA, Shaffer DJ, Roopenian D, Wilson SB, Serreze DV. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J Immunol 2005;174:1196-204.
14. Takagi D, Iwabuchi K, Maeda M, Nakamaru Y, Furuta Y, Fukuda S, Van Kaer L, Nishihira J, Onoe K. Natural killer T cells ameliorate antibody-induced arthritis in macrophage migration inhibitory factor transgenic mice. Int J Mol Med 2006;18:829-36.
15. Kim HY, Kim HJ, Min HS, Kim S, Park WS, Park SH, Chung DH. NKT cells promote antibody-induced joint inflammation by suppressing transforming growth factor β1 production. J Exp Med 2005;201:41-7.
16. van der Vliet HJJ, von Blomberg BM, Nishi N, Reijm M, Voskuyl AE, van Bodegraven AA, Polman CH, Rustemeyer T, Lips P, van den Eertwegh AJM. Circulating V[α]24+ V[β]11+ NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol 2001;100:144-8.
17. Molling JW, Kolgen W, van der Vliet HJ, Boomsma MF, Kruizenga H, Smorenburg CH, Molenkamp BG, Langendijk JA, Leemans CR, von Blomberg BM, Scheper RJ, van den Eertwegh AJ. Peripheral blood IFN-γ-secreting Vα24+Vβ11+NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer 2005;116:87-93.
18. Molling JW, Langius JAE, Langendijk JA, Leemans CR, Bontkes HJ, van der Vliet HJJ, von Blomberg BME, Scheper RJ, van den Eertwegh AJM. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol, 2007;25:862-868.
19. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
20. Stern PL. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol 2005;32(Suppl 1):S72-S81.
21. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20-5.
22. de Gruijl TD, Bontkes HJ, Walboomers JM, Stukart MJ, Doekhie FS, Remmink AJ, Helmerhorst TJ, Verheijen RH, Duggan-Keen MF, Stern PL, Meijer CJ, Scheper RJ. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res 1998;58:1700-6.
23. Bontkes HJ, de Gruijl TD, van den Muysenberg AJ, Verheijen RH, Stukart MJ, Meijer CJ, Scheper RJ, Stacey SN, Duggan-Keen MF, Stern PL, Man S, Borysiewicz, LK, et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer 2000;88:92-8.
24. Remmink AJ, Walboomers JM, Helmerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK, Meijer CJ, Kenemans P. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995;61:306-11.
25. Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995;76 (Part 4):1057-62.
26. Roda Husman AM, Walboomers JM, Meijer CJ, Risse EK, Schipper ME, Helmerhorst TM, Bleker OP, Delius H, van den Brule AJ, Snijders PJ. Analysis of cytomorphologically abnormal cervical scrapes for the presence of 27 mucosotropic human papillomavirus genotypes, using polymerase chain reaction. Int J Cancer 1994;56:802-6.
27. Karadimitris A, Gadola S, Altamirano M, Brown D, Woolfson A, Klenerman P, Chen JL, Koezuka Y, Roberts IA, Price DA, Dusheiko G, Milstein C, et al. Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc Natl Acad Sci USA 2001;98:3294-8.
28. +CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005;174:164-73.
29. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006;24:1169-77.
30. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG, Levings MK. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007;19:345-54.
31. + T cells. Clin Immunol 2005;115:10-18.
32. Motohashi S, Kobayashi S, Ito T, Magara KK, Mikuni O, Kamada N, Iizasa T, Nakayama T, Fujisawa T, Taniguchi M. Preserved IFN-α production of circulating Vα 24 NKT cells in primary lung cancer patients. Int J Cancer 2002;102:159-65.
33. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MA. Loss of IFN-γ production by invariant NK T cells in advanced cancer. J Immunol 2001;167:4046-50.
34. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ, Roelvink M, Beijnen J, et al. A phase I study of the natural killer T-cell ligand α- galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002;8:3702-9.
35. van der Vliet HJJ, van Vonderen MGA, Molling JW, Bontkes HJ, Reijm M, Reiss P, van Agtmael MA, Danner SA, van den Eertwegh AJM, von Blomberg BM, Scheper RJ. Cutting edge: rapid recovery of NKT cells upon institution of highly active antiretroviral therapy for HIV-1 infection. J Immunol 2006;177:5775-8.
36. van der Vliet HJ, Molling JW, von Blomberg BM, Kolgen W, Stam AG, de Gruijl TD, Mulder CJ, Janssen HL, Nishi N, van den Eertwegh AJ, Scheper RJ, van Nieuwkerk CJ. Circulating Vα24+Vβ11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients. Clin Immunol 2005;114:183-9.
37. Huber SA, Feldman AM, Sartini D. Coxsackievirus B3 induces T regulatory cells, which inhibit cardiomyopathy in tumor necrosis factor-α transgenic mice. Circ Res 2006;99:1109-16.
38. + regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006;177:739-47.
39. + regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 2004;104:3249-56.
40. + T cells during persistent hepatitis C virus infection. J Virol 2005;79:7852-9.
41. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003;38:1437-48.
42. + T cells during chronic hepatitis C virus infection. J Virol 2005;79:7860-7.
43. Ling KL, Pratap SE, Bates GJ, Singh B, Mortensen NJ, George BD, Warren BF, Piris J, Roncador G, Fox SB, Banham AH, Cerundolo V. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 2007;7:7.
44. + regulatory T cells through a STAT dependent mechanism and induces the expansion of these cells in vivo. Blood 2006;108:1571-9.
45. Taylor JJ, Mohrs M, Pearce EJ. Regulatory T cell responses develop in parallel to Th responses and control the magnitude and phenotype of the Th effector population. J Immunol 2006;176:5839-47.
46. Hiura T, Kagamu H, Miura S, Ishida A, Tanaka H, Tanaka J, Gejyo F, Yoshizawa H. Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J Immunol 2005;175:5058-66.
47. Schreurs MW, Scholten KB, Kueter EW, Ruizendaal JJ, Meijer CJ, Hooijberg E. In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones. J Immunol 2003;171:2912-21.
48. + tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007;67:354-61.
49. Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, Omata H, Fujii H. CD4(+)CD25 high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006;55:1064-71.